RFS Pharma will utilize its strong scientific talent and know-how to develop promising drugs for the treatment of life-threatening illnesses where there is substantial and growing unmet medical need.
Background
RFS Pharma, LLC is a clinical-stage biopharmaceutical company founded by Dr. Raymond F. Schinazi to develop new drugs for the treatment of HIV-1 and hepatitis infections as well as emerging viruses. Located in a laboratory facility in suburban Atlanta, RFS Pharma will continue to provide growth to the pharmaceutical industry in Georgia.
Incorporated in 2004, RFS Pharma in-licensed a series of anti-HIV drugs including Amdoxovir® (AMDX, DAPD) from Emory University and the University of Georgia Research Foundation. In advanced Phase II clinical studies, DAPD is effective at lowering HIV load, even in individuals with resistant virus strains. DAPD may also be effective for the treatment of hepatitis B virus (HBV).
